- Home
- HR vs CNTA Comparison
HR vs CNTA Comparison
Compare HR & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HR | CNTA |
|---|---|---|
| Founded | 1992 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 6.1B |
| IPO Year | 2006 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HR | CNTA |
|---|---|---|
| Price | $19.96 | $39.75 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $19.29 | ★ $43.17 |
| AVG Volume (30 Days) | ★ 4.6M | 1.1M |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.20% | N/A |
| EPS Growth | ★ 60.77 | 29.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,180,546,000.00 | $15,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.14 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.09 | $10.95 |
| 52 Week High | $20.61 | $40.26 |
Technical Indicators
Market Signals| Indicator | HR | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 55.38 | 70.14 |
| Support Level | $17.38 | $39.36 |
| Resistance Level | $20.46 | $39.86 |
| Average True Range (ATR) | 0.32 | 0.09 |
| MACD | -0.10 | -0.19 |
| Stochastic Oscillator | 28.98 | 67.19 |
Price Performance
Historical ComparisonAbout HR Healthcare Realty Trust Incorporated
Healthcare Realty Trust Inc is a healthcare facility real estate investment trust. The company focuses on owning, leasing, and managing outpatient facilities and other healthcare properties. The company works to invest in outpatient facilities that are integral to a hospital's operations. It generates all of its revenue in the United States.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.